Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche Raises IO Credentials On Tecentriq Lung Cancer Data

Executive Summary

With positive overall survival data from the Phase III OAK trial of Tecentriq in non-small cell lung cancer, Roche enters the top flight of immuno-oncology companies alongside Merck and Bristol-Myers Squibb.

Advertisement

Related Content

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Roche: OAK Data Differentiates Tecentriq In Second-Line Lung Cancer
Opdivo Fallout: Rivalry In PD-1 Market To Continue, More Trials Could Mean More Failures
Does CheckMate 026 Take Bristol Out Of The End Game?
Roche Sees Cancer Combos Start To Deliver

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel